Filing Details
- Accession Number:
- 0000950170-24-041842
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-04-04 16:30:41
- Reporting Period:
- 2024-04-02
- Accepted Time:
- 2024-04-04 16:30:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1782303 | Boundless Bio Inc. | BOLD | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1219039 | Keith Crandell | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | No | No | |
| 1219042 | Robert Nelsen | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | No | No | |
| 1219043 | Clinton Bybee | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | No | No | |
| 1229592 | Steven Gillis | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-04-02 | 589,743 | $0.00 | 617,092 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2024-04-02 | 787,545 | $0.00 | 828,570 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2024-04-02 | 1,048,433 | $0.00 | 1,048,433 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2024-04-02 | 66,667 | $16.00 | 683,759 | No | 4 | P | Indirect | See footnotes |
| Common Stock | Acquisiton | 2024-04-02 | 133,333 | $16.00 | 1,181,766 | No | 4 | P | Indirect | See footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnotes |
| No | 4 | C | Indirect | See footnotes |
| No | 4 | C | Indirect | See footnotes |
| No | 4 | P | Indirect | See footnotes |
| No | 4 | P | Indirect | See footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2024-04-02 | 424,908 | $0.00 | 424,908 | $0.00 |
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2024-04-02 | 586,080 | $0.00 | 586,080 | $0.00 |
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2024-04-02 | 454,212 | $0.00 | 454,212 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2024-04-02 | 227,920 | $0.00 | 227,920 | $0.00 |
| Common Stock | Series C Convertible Preferred Stock | Disposition | 2024-04-02 | 164,835 | $0.00 | 164,835 | $0.00 |
| Common Stock | Series C Convertible Preferred Stock | Disposition | 2024-04-02 | 201,465 | $0.00 | 201,465 | $0.00 |
| Common Stock | Series C Convertible Preferred Stock | Disposition | 2024-04-02 | 366,301 | $0.00 | 366,301 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
- Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
- Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
- ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
- Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
- ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
- Reflects shares purchased by ARCH IX in the Issuer's initial public offering.
- Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering.
Billionaire Hedge Funds
